Aurel Capital works with researchers, scientists, clinicians and physician-scientists on ideas with the potential to improve human health.
Not every breakthrough becomes a company.
Some become patents.
Some become licensed technologies.
Some improve standards of care.
Some become the foundation for future discoveries.
Whatever the outcome, we believe significant research deserves thoughtful strategy and the right ecosystem to maximize its impact.
Three things get decided before any money arrives, whichever way it goes.
Who owns the intellectual property. Under most institutional policies, that is your institution rather than you, and faculty agreements usually assign inventions automatically.
What you have already published, and when. A paper that goes out before a patent is filed can quietly end the patent.
What your technology transfer office will want in return. Its duty runs to the institution, so it is a negotiation rather than a form.
The money itself is usually not investment. For most work at this stage the right first step is non-dilutive.
BIRAC's BIG scheme funds individuals and young companies up to ₹50 lakh over 18 months and is open to scientists, faculty and research scholars, and DBT and ICMR run parallel routes. Taking equity money too early, against thin evidence, sets a price the science cannot grow into.
How We Collaborate
Working out which path the research is actually on: a grant, a licence, a company, or more evidence first
Sequencing publication and filing so disclosure does not cost you the patent
Handling the technology transfer conversation as a negotiation
Evaluating translational, regulatory, commercialization, licensing and partnership pathways
Working alongside academic institutions, hospitals, industry partners and investors
Contributing to research initiatives, publications and investment theses
Who We Collaborate With
Academic researchers, principal investigators, postdoctoral researchers and hospital-based researchers
Physician